Arctic Bioscience - First patient included in HRO350 Phase IIb clinical trial in the UK

01 Feb 2023 07:30 CET

Reference is being made to the stock exchange release from January 12[th] 2023
where Arctic Bioscience announced that the Clinical Trial Application (CTA) for
a Phase IIb clinical trial in mild-to-moderate psoriasis with the
investigational medicinal product (IMP) HRO350 was approved in the United
Kingdom (UK).

Arctic Bioscience has met a key milestone in the drug development program for
HRO350. The first patient has been included in the clinical trial "A phase IIb,
multicenter, randomized, double-blind, placebo-controlled, dose-finding,
efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis"
(the 'HeROPA' study) in the UK. This is the start of the clinical study.

"This is the kickoff. Our innovative and highly competent team has been working
diligently for several years towards this breakthrough. Following the successful
approval from the UK medicines authorities, a clinic in the UK has included the
first patient. This is a great occasion for Arctic Bioscience, which was listed
on EuroNext Growth in 2021 raising funds to conduct this study", comments
Christer L. Valderhaug, CEO of Arctic Bioscience.

The international study is planned to be conducted in five countries, with a
total of 519 patients. A six-month inclusion period is expected, with first data
readout six months after last patient is included.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO of Arctic Bioscience AS

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

Jone R. Slinning

CFO of Arctic Bioscience AS

Mobile: +47 948 75 469

Email: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.

More information:
Access the news on Oslo Bors NewsWeb site